BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 16502177)

  • 1. The role of N-acetylcysteine in the prevention of contrast-induced nephrotoxicity.
    Sandhu C; Belli AM; Oliveira DB
    Cardiovasc Intervent Radiol; 2006; 29(3):344-7. PubMed ID: 16502177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial.
    Kay J; Chow WH; Chan TM; Lo SK; Kwok OH; Yip A; Fan K; Lee CH; Lam WF
    JAMA; 2003 Feb; 289(5):553-8. PubMed ID: 12578487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is treatment with N-acetylcysteine to prevent contrast-induced nephropathy when using bicarbonate hydration out of date?
    Heng AE; Cellarier E; Aublet-Cuvelier B; Decalf V; Motreff P; Marcaggi X; Deteix P; Souweine B
    Clin Nephrol; 2008 Dec; 70(6):475-84. PubMed ID: 19049703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease.
    Solomon RJ; Natarajan MK; Doucet S; Sharma SK; Staniloae CS; Katholi RE; Gelormini JL; Labinaz M; Moreyra AE;
    Circulation; 2007 Jun; 115(25):3189-96. PubMed ID: 17562951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast.
    Boccalandro F; Amhad M; Smalling RW; Sdringola S
    Catheter Cardiovasc Interv; 2003 Mar; 58(3):336-41. PubMed ID: 12594698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-Acetylcysteine added to volume expansion with sodium bicarbonate does not further prevent contrast-induced nephropathy: results from the cardiac angiography in renally impaired patients study.
    Staniloae CS; Doucet S; Sharma SK; Katholi RE; Mody KR; Coppola JT; Solomon R
    J Interv Cardiol; 2009 Jun; 22(3):261-5. PubMed ID: 19490358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography.
    Oldemeyer JB; Biddle WP; Wurdeman RL; Mooss AN; Cichowski E; Hilleman DE
    Am Heart J; 2003 Dec; 146(6):E23. PubMed ID: 14661012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prehydration alone is sufficient to prevent contrast-induced nephropathy after day-only angiography procedures--a randomised controlled trial.
    Kotlyar E; Keogh AM; Thavapalachandran S; Allada CS; Sharp J; Dias L; Muller D
    Heart Lung Circ; 2005 Dec; 14(4):245-51. PubMed ID: 16360994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Contrast nephropathy in cardiac procedures: no advantages with prophylactic use of N-acetylcysteine (NAC)].
    Vallero A; Cesano G; Pozzato M; Garbo R; Minelli M; Quarello F; Formica M
    G Ital Nefrol; 2002; 19(5):529-33. PubMed ID: 12439841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nephrotoxic effects of iodixanol and iopromide in patients with abnormal renal function receiving N-acetylcysteine and hydration before coronary angiography and intervention: a randomized trial.
    Juergens CP; Winter JP; Nguyen-Do P; Lo S; French JK; Hallani H; Fernandes C; Jepson N; Leung DY
    Intern Med J; 2009 Jan; 39(1):25-31. PubMed ID: 18771430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure.
    Shyu KG; Cheng JJ; Kuan P
    J Am Coll Cardiol; 2002 Oct; 40(8):1383-8. PubMed ID: 12392825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylaxis of contrast-induced nephropathy in patients undergoing coronary angiography.
    MacNeill BD; Harding SA; Bazari H; Patton KK; Colon-Hernadez P; DeJoseph D; Jang IK
    Catheter Cardiovasc Interv; 2003 Dec; 60(4):458-61. PubMed ID: 14624421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved estimation of glomerular filtration rate by serum cystatin C in preventing contrast induced nephropathy by N-acetylcysteine or zinc--preliminary results.
    Kimmel M; Butscheid M; Brenner S; Kuhlmann U; Klotz U; Alscher DM
    Nephrol Dial Transplant; 2008 Apr; 23(4):1241-5. PubMed ID: 18174269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of contrast-induced nephropathy by N-acetylcysteine in critically ill patients: different definitions, different results.
    Chousterman BG; Bouadma L; Moutereau S; Loric S; Alvarez-Gonzalez A; Mekontso-Dessap A; Laissy JP; Rahmouni A; Katsahian S; Brochard L; Schortgen F
    J Crit Care; 2013 Oct; 28(5):701-9. PubMed ID: 23683568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylaxis of contrast material-induced nephropathy in patients in intensive care: acetylcysteine, theophylline, or both? A randomized study.
    Huber W; Eckel F; Hennig M; Rosenbrock H; Wacker A; Saur D; Sennefelder A; Hennico R; Schenk C; Meining A; Schmelz R; Fritsch R; Weiss W; Hamar P; Heemann U; Schmid RM
    Radiology; 2006 Jun; 239(3):793-804. PubMed ID: 16714461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy.
    Allaqaband S; Tumuluri R; Malik AM; Gupta A; Volkert P; Shalev Y; Bajwa TK
    Catheter Cardiovasc Interv; 2002 Nov; 57(3):279-83. PubMed ID: 12410497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acetylcysteine, coronary procedure and prevention of contrast-induced worsening of renal function: which benefit for which patient?
    Kefer JM; Hanet CE; Boitte S; Wilmotte L; De Kock M
    Acta Cardiol; 2003 Dec; 58(6):555-60. PubMed ID: 14713182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acetylcysteine and non-ionic isosmolar contrast-induced nephropathy--a randomized controlled study.
    Ferrario F; Barone MT; Landoni G; Genderini A; Heidemperger M; Trezzi M; Piccaluga E; Danna P; Scorza D
    Nephrol Dial Transplant; 2009 Oct; 24(10):3103-7. PubMed ID: 19549691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ACTIVE Trial: comparison of the effects on renal function of iomeprol-400 and iodixanol-320 in patients with chronic kidney disease undergoing abdominal computed tomography.
    Thomsen HS; Morcos SK; Erley CM; Grazioli L; Bonomo L; Ni Z; Romano L;
    Invest Radiol; 2008 Mar; 43(3):170-8. PubMed ID: 18301313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of N-acetylcysteine on cystatin C-based renal function after elective coronary angiography (ENABLE Study): a prospective, randomized trial.
    Kim BJ; Sung KC; Kim BS; Kang JH; Lee KB; Kim H; Lee MH
    Int J Cardiol; 2010 Feb; 138(3):239-45. PubMed ID: 18793808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.